iPSC-based drug screening for Huntington's disease

Area of Science:

• Neurodegenerative Disorders
• Genetics
• Stem Cell Biology

Background:

• Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene.
• HD presents with physical and mental symptoms in middle age, with no current cure and a fatal prognosis.
• Understanding HD pathogenesis has been advanced by various research models since the gene's identification in 1993.

Purpose of the Study:

• To review the historical development of Huntington's disease models.
• To discuss current stem cell-based models, particularly those derived from induced pluripotent stem cells (iPSCs) of HD patients.
• To explore future directions in modeling HD using iPSC technology and genome editing.

Main Methods:

• Review of existing literature on Huntington's disease models.
• Focus on the application of induced pluripotent stem cells (iPSCs) derived from Huntington's disease patients.
• Discussion of genome editing technologies in conjunction with stem cell models.

Main Results:

• Induced pluripotent stem cells (iPSCs) from HD patients provide unprecedented cellular and developmental insights.
• Stem cell models offer diverse screening and research options previously unavailable.
• The integration of genome editing with stem cell technology is expanding the repertoire of HD models.

Conclusions:

• Patient-derived iPSCs represent a significant advancement in modeling Huntington's disease.
• These models facilitate a deeper characterization of HD at the cellular level.
• Future research leveraging iPSCs and genome editing holds promise for developing effective treatments for Huntington's disease.